- Home
- YJ vs SLXN Comparison
YJ vs SLXN Comparison
Compare YJ & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YJ
- SLXN
- Stock Information
- Founded
- YJ 2015
- SLXN 2008
- Country
- YJ China
- SLXN Israel
- Employees
- YJ N/A
- SLXN N/A
- Industry
- YJ Other Specialty Stores
- SLXN
- Sector
- YJ Consumer Discretionary
- SLXN
- Exchange
- YJ Nasdaq
- SLXN NYSE
- Market Cap
- YJ 8.8M
- SLXN 5.0M
- IPO Year
- YJ 2019
- SLXN N/A
- Fundamental
- Price
- YJ $1.84
- SLXN $1.26
- Analyst Decision
- YJ
- SLXN Strong Buy
- Analyst Count
- YJ 0
- SLXN 1
- Target Price
- YJ N/A
- SLXN $9.00
- AVG Volume (30 Days)
- YJ 45.2K
- SLXN 32.1M
- Earning Date
- YJ 03-20-2025
- SLXN 02-21-2025
- Dividend Yield
- YJ N/A
- SLXN N/A
- EPS Growth
- YJ N/A
- SLXN N/A
- EPS
- YJ N/A
- SLXN N/A
- Revenue
- YJ $66,957,730.00
- SLXN N/A
- Revenue This Year
- YJ N/A
- SLXN N/A
- Revenue Next Year
- YJ N/A
- SLXN N/A
- P/E Ratio
- YJ N/A
- SLXN N/A
- Revenue Growth
- YJ N/A
- SLXN N/A
- 52 Week Low
- YJ $1.42
- SLXN $0.21
- 52 Week High
- YJ $4.72
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- YJ 53.54
- SLXN N/A
- Support Level
- YJ $1.68
- SLXN N/A
- Resistance Level
- YJ $1.93
- SLXN N/A
- Average True Range (ATR)
- YJ 0.13
- SLXN 0.00
- MACD
- YJ 0.02
- SLXN 0.00
- Stochastic Oscillator
- YJ 69.70
- SLXN 0.00
About YJ Yunji Inc. American Depository Shares
Yunji Inc is a social e-commerce platform in China that offers a membership-based model that leverages the power of social interaction. The company provides a host of selected commodities such as beauty and personal care, mobile phones and digital products, baby and maternal products, toys, fruits, and other fresh products. It has expanded to operate its business, including the marketplace, on a diverse range of sales channels and other platforms. Geographically, the firm operates in China.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.